Improving Relapse Prediction in Inflammatory Bowel Disease by Neutrophil-Derived S100A12

Abstract

Regular measurements of fecal S100A12 levels reliably detect inflammatory bowel disease relapse at an early stage, which makes the test a promising noninvasive tool for monitoring and optimizing therapy, and may reduce the need for invasive investigations during disease follow-up.